VLS Semaglutide 5mg (GLP-1 Weight Loss Pen)

VLS Semaglutide 5mg is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and promotes significant fat loss. Originally developed for type 2 diabetes management, Semaglutide gained widespread attention after the STEP 1 clinical trial (NEJM, 2021) demonstrated an average weight loss of 14.9% of body weight over 68 weeks at the 2.4mg weekly dose. It is now one of the most sought-after weight management compounds worldwide.

How Semaglutide Works

Semaglutide mimics the naturally occurring hormone GLP-1 (glucagon-like peptide-1), which is released by the gut after eating. GLP-1 signals the brain’s appetite centres to reduce hunger, slows the rate at which food leaves the stomach (increasing satiety), and improves insulin sensitivity. The result is a substantial and sustained reduction in caloric intake without the willpower-dependent struggle of traditional dieting.

Unlike stimulant-based fat burners such as Clenbuterol, Semaglutide does not raise heart rate, cause jitteriness, or disrupt sleep. It works through a hormonal satiety pathway rather than CNS stimulation, making it suitable for users who cannot tolerate stimulants or who want to combine it with other compounds without compounding cardiovascular stress.

Dosage Protocol

Semaglutide requires a gradual dose escalation to minimise gastrointestinal side effects (primarily nausea):

• Week 1-4: 0.25mg once weekly (tolerance-building phase)
• Week 5-8: 0.5mg once weekly
• Week 9-12: 1.0mg once weekly
• Week 13+: 1.7-2.4mg once weekly (maintenance/target dose)
• Administration: subcutaneous injection, typically in the abdomen or thigh. Same day each week
• This 5mg vial provides: approximately 10-20 weeks of supply depending on dose titration

Who Benefits from Semaglutide

• Bodybuilders in cutting phases who want appetite suppression without stimulant side effects
• Users running bulking compounds who need to control appetite rebound after cycle (post-Dbol bloat management)
• General weight management for individuals with BMI above 27 who struggle with appetite control
• Users who cannot tolerate Clenbuterol due to cardiovascular sensitivity, insomnia, or anxiety

Side Effects

• Nausea: most common side effect, particularly during dose escalation. Resolves for most users after 2-4 weeks at each dose level. Taking the injection at bedtime can reduce daytime nausea
• Constipation or diarrhoea: gastrointestinal adjustment. Usually temporary
• Reduced appetite: this is the intended effect but can be extreme at higher doses. Ensure minimum protein intake (2g/kg bodyweight) to prevent muscle loss
• Injection site reactions: mild redness or itching at the injection site. Rotate sites
• Pancreatitis risk: rare but documented. Seek medical attention for severe, persistent abdominal pain

Key Facts

• Active ingredient: Semaglutide 5mg per vial
• Manufacturer: VLS
• Class: GLP-1 receptor agonist
• Half-life: approximately 7 days (once-weekly dosing)
• Testosterone suppression: none
• PCT required: no
• Liver toxicity: none

Browse our full weight loss range including Clenbuterol, T3, Tirzepatide, and Retatrutide. For steroid-based cutting, read our Anavar Guide.